EcoDrugPlus

Selectin E

Ensembl ID : ENSTNIG00000019644
Gene Symbol: SELE
2 Cross references
185 Possible Orthologues:

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSTNIG00000003214
Gene Symbol: SERPINC1
2 Cross references
199 Possible Orthologues:

Si:dkey-91m11.5

Ensembl ID : ENSTNIG00000011444
Gene Symbol: SI:DKEY-91M11.5
2 Cross references
196 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSTNIG00000007582
Gene Symbol: SMO
2 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSTNIG00000003563
Gene Symbol: SCN5LAB
2 Cross references
62 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSTNIG00000006684
Gene Symbol: SCN5LAB
2 Cross references
73 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSTNIG00000007916
Gene Symbol: SCN12AA
2 Cross references
71 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSTNIG00000005129
Gene Symbol: SCN4A
2 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSTNIG00000015105
Gene Symbol: SCN8A
3 Cross references
215 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSTNIG00000017826
Gene Symbol: SLC10A2
2 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSTNIG00000002535
Gene Symbol: SLC18A2
2 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSTNIG00000005073
Gene Symbol: SLC29A1
2 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).